Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2019 16:05 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
October 17, 2019 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences

CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
September 03, 2019 16:05 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
August 13, 2019 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress

On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc....
August 07, 2019 16:05 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Announce Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
July 25, 2019 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy

CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
June 05, 2019 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs

CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
May 28, 2019 16:05 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
May 15, 2019 08:00 ET | Source: Rubius Therapeutics

Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress

Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces Transition of President Torben...
May 06, 2019 16:05 ET | Source: Rubius Therapeutics

Rubius Therapeutics to Announce First Quarter 2019 Financial Results

CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right